Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,019 | 173 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $567.26 | 39 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $241.35 | 24 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $153.76 | 18 | $0 (2018) |
| Novo Nordisk Inc | $140.84 | 11 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $134.67 | 11 | $0 (2018) |
| ABBVIE INC. | $120.28 | 6 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $91.37 | 7 | $0 (2018) |
| Lilly USA, LLC | $89.48 | 7 | $0 (2018) |
| Amarin Pharma Inc. | $88.82 | 7 | $0 (2019) |
| Amgen Inc. | $81.77 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $94.80 | 5 | ABBVIE INC. ($81.04) |
| 2023 | $57.43 | 3 | GlaxoSmithKline, LLC. ($30.82) |
| 2022 | $60.21 | 4 | GlaxoSmithKline, LLC. ($47.58) |
| 2021 | $20.83 | 1 | GlaxoSmithKline, LLC. ($20.83) |
| 2020 | $40.94 | 3 | GlaxoSmithKline, LLC. ($14.33) |
| 2019 | $207.21 | 12 | GlaxoSmithKline, LLC. ($129.12) |
| 2018 | $485.15 | 44 | GlaxoSmithKline, LLC. ($149.42) |
| 2017 | $1,052 | 101 | Merck Sharp & Dohme Corporation ($228.43) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: RESPIRATORY | ||||||
| 05/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.61 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: RESPIRATORY | ||||||
| 03/01/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: RESPIRATORY | ||||||
| 04/28/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: RESPIRATORY | ||||||
| 04/06/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: RESPIRATORY | ||||||
| 02/10/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: RESPIRATORY | ||||||
| 12/16/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: RESPIRATORY | ||||||
| 04/07/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: RESPIRATORY | ||||||
| 03/09/2020 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Diabetes | ||||||
| 01/27/2020 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/13/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: RESPIRATORY | ||||||
| 09/03/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: RESPIRATORY | ||||||
| 06/27/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: RESPIRATORY | ||||||
| 05/30/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: RESPIRATORY | ||||||
| 03/14/2019 | Coloplast Corp | ALTIS (Device) | Food and Beverage | Cash or cash equivalent | $22.68 | General |
| Category: FEMALE INCONTINENCE | ||||||
| 03/13/2019 | Amgen Inc. | Aimovig (Biological), Repatha | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Neuroscience | ||||||
| 03/06/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: Central Nervous System (CNS) | ||||||
| 03/05/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: Central Nervous System (CNS) | ||||||
| 03/05/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $1.12 | General |
| Category: Central Nervous System (CNS) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,107 | 1,956 | $281,363 | $130,715 |
| 2022 | 9 | 957 | 1,803 | $238,993 | $93,380 |
| 2021 | 9 | 1,068 | 2,030 | $247,853 | $95,575 |
| 2020 | 18 | 1,210 | 2,040 | $253,124 | $79,980 |
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 278 | 935 | $155,548 | $57,361 | 36.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 128 | 129 | $37,539 | $36,464 | 97.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 196 | 196 | $66,282 | $23,640 | 35.7% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 115 | 116 | $4,292 | $3,318 | 77.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 209 | 381 | $3,810 | $3,200 | 84.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 98 | 101 | $2,929 | $2,870 | 98.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 13 | 16 | $5,790 | $1,699 | 29.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 15 | 15 | $1,935 | $1,076 | 55.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 23 | $2,880 | $990.70 | 34.4% |
| 81003 | Automated urinalysis test | Office | 2023 | 33 | 44 | $358.00 | $96.80 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 292 | 938 | $160,432 | $57,715 | 36.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 192 | 192 | $59,904 | $23,688 | 39.5% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 17 | 17 | $4,947 | $4,727 | 95.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 118 | 121 | $3,469 | $3,228 | 93.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 240 | 431 | $4,310 | $1,278 | 29.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 14 | 14 | $1,806 | $959.56 | 53.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 19 | $2,618 | $857.30 | 32.7% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 31 | 31 | $1,147 | $839.01 | 73.1% |
| 81003 | Automated urinalysis test | Office | 2022 | 36 | 40 | $360.00 | $88.71 | 24.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 314 | 958 | $160,388 | $62,194 | 38.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 204 | 204 | $63,648 | $25,800 | 40.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 54 | 61 | $9,062 | $2,906 | 32.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 93 | 97 | $1,843 | $1,515 | 82.2% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2021 | 13 | 14 | $5,292 | $1,487 | 28.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 311 | 608 | $6,080 | $1,160 | 19.1% |
About Dr. Kimberly Baldock, MD
Dr. Kimberly Baldock, MD is a Internal Medicine healthcare provider based in Ashland, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1144225657.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kimberly Baldock, MD has received a total of $2,019 in payments from pharmaceutical and medical device companies, with $94.80 received in 2024. These payments were reported across 173 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,019).
As a Medicare-enrolled provider, Baldock has provided services to 4,342 Medicare beneficiaries, totaling 7,829 services with total Medicare billing of $399,650. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Ashland, KY
- Active Since 06/21/2005
- Last Updated 01/12/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144225657
Products in Payments
- TRELEGY ELLIPTA (Drug) $310.15
- BREO (Drug) $234.88
- JANUVIA (Drug) $177.86
- XARELTO (Drug) $141.95
- FARXIGA (Drug) $134.67
- VRAYLAR (Drug) $120.28
- Vascepa (Drug) $88.82
- JARDIANCE (Drug) $69.70
- Amitiza (Drug) $65.59
- TRULICITY (Drug) $63.51
- Victoza (Drug) $56.05
- BELSOMRA (Drug) $54.88
- Saxenda (Drug) $49.19
- Prolia (Biological) $48.86
- Dexilant (Drug) $47.36
- SOLIQUA (Drug) $41.03
- Trintellix (Drug) $34.20
- TOUJEO (Drug) $26.42
- PRALUENT (Drug) $23.92
- ALTIS (Device) $22.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ashland
Dr. Basel Edris, Md, MD
Internal Medicine — Payments: $42,620
Dr. Kenneth Leung, M.d, M.D
Internal Medicine — Payments: $10,085
Dr. Mehrdad Tavallaee, Md, MD
Internal Medicine — Payments: $6,878
Diane Settles, Md, MD
Internal Medicine — Payments: $6,278
Alexandr Karimov, M.d, M.D
Internal Medicine — Payments: $5,982
Roger Klein, M.d, M.D
Internal Medicine — Payments: $5,835